EUVIMEDEUVIMED entdecken
Crossref

Role of Ubiquitin-specific Protease 1 in the Pathogenesis and Treatment of Adult T-Cell Leukemia

Chie Ishikawa, Naoki Mori

Anticancer Research · 2025

DOI: 10.21873/anticanres.17831 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Chie Ishikawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan. Hauptthemen laut MEDLINE: Leukemia-Lymphoma, Adult T-Cell, Ubiquitin-Specific Proteases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: We previously reported the therapeutic potential of pimozide against adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type 1 (HTLV-1). Pimozide inhibits ubiquitin-specific protease 1 (USP1). In this study, we investigated the functional significance of USP1 and its potential as a therapeutic target for ATL treatment. MATERIALS AND METHODS: Cellular processes, including proliferation, metabolism, apoptosis, and the expression of USP1 and related regulatory proteins, were assessed. RESULTS: HTLV-1-infected T cells showed aberrant USP1 protein expression, and USP1 knockdown significantly inhibited their proliferation. Similarly, treatment with pimozide and the USP1 inhibitor SJB3-019A reduced USP1 expression, inhibiting cell proliferation and survival. SJB3-019A decreased the expression of c-Myc, a USP1 target, resulting in G1 cell cycle arrest. Furthermore, it induced caspase-mediated apoptosis by suppressing anti-apoptotic proteins, as well as mitochondrial dysfunction, ROS production, endoplasmic reticulum stress, and DNA damage. SJB3-019A led to a reduction in the critical glycolytic enzyme LDHA, decreasing lactate levels. Additionally, SJB3-019A inhibited the expression of polo-like kinase 1, another USP1 target and a kinase upstream of LDHA and c-Myc. SJB3-019A also suppressed β-catenin expression and IĸBα, RelA, and Akt phosphorylation, indicating NF-ĸB/Akt inhibition. CONCLUSION: Our study supports the clinical potential of USP1 inhibitors as a novel therapy for ATL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia-Lymphoma, Adult T-CellUbiquitin-Specific ProteasesHumansApoptosisCell ProliferationHuman T-lymphotropic virus 1Cell Line, TumorSignal Transduction

Stichwörter der Autor:innen

Adult T-cell leukemiaSJB3-019Ahuman T-cell leukemia virus type 1ubiquitin-specific protease 1

Substanzen

Ubiquitin-Specific ProteasesUSP1 protein, human

Autor:innen und Institutionen

  • Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan.
  • Research Facility Center, University of the Ryukyus, Nishihara, Japan.
  • Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan; naokimori50@gmail.com.

Zitieren

APA

Ishikawa, C., & Mori, N. (2025). Role of Ubiquitin-specific Protease 1 in the Pathogenesis and Treatment of Adult T-Cell Leukemia. Anticancer Research. https://doi.org/10.21873/anticanres.17831

Vancouver

Ishikawa C, Mori N. Role of Ubiquitin-specific Protease 1 in the Pathogenesis and Treatment of Adult T-Cell Leukemia. Anticancer Research. 2025. doi:10.21873/anticanres.17831

BibTeX
@article{Ishikawa2025,
  author = {Ishikawa, Chie and Mori, Naoki},
  title = {Role of Ubiquitin-specific Protease 1 in the Pathogenesis and Treatment of Adult T-Cell Leukemia},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17831}
}
Kostenlos starten →